FDA warning on Chantix with CAD

The FDA has issued a warning of the increased risk of cardiac events (primarily MI) in patients on Chantix. They are requiring the manufacturer to perform a meta-analysis to quantify the risk. For now, prescribers should use Chantix with caution in patients at risk for, or know, CAD (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment